(OS) and disease-free survival (DFS) of these patients after ASCT. Patients and Methods: 16 patients with refractory/relapsed (<6 months) stage III (FIGO) OC were enrolled in our HDC program, after standard salvage t herapy; median age 46 yrs (29-63), ECOG PS 0-1. They received high dose (HD) cyclophosphamide or epirubicin + Ifosfamide and G-CSF to mobilize and collect peripheral blood stem cells. Then they received HDC, before ASCT, as follows:
68% for Arm B. With a median survival observation time of 37 months there was no difference in 6-year probability of survival (60% and 58%), of disease-free survival (DFS) [54.5% and 65.5% for Arm A and B (p=0.7), respectively] and of progressionfree survival (PFS) [41.3% and 49.5% for Arm A and B (p=0.9) , respectively] . Stratification of pts according to the IPI adjusted for age < 60 years showed a statistical better outcome in terms of survival (p=0.0000) and of PFS (p=0.0001) for lower-risk pts (0-1 neg factors) versus higher-risk pts (2-3 neg factors), without any statistical difference according to the treatment received. Patients with BM involvement or with T-cell NHL showed the poorest results. Retrospective analysis only including the categories of pts reported in previous randomised studies showed an improvement of our results, in line with data published before. Two pts died in Arm A (2%) and 3 in Arm B (3%) because of procedure, respectively In conclusion, this study confirm HDS data only in a selected group of pts with large B -cell NHL without BM involvement. There is no difference in using HDS plus ASCT after CT in all cases or only in the case of persistent disease, even in higherrisk pts.
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Allogeneic stem cell transplantation after a reducedintensity conditioning regimen vs conventional allogeneic stem cell transplantation in Hodgkin's disease: results of the European Group for Blood and Marrow Transplantation A. Sureda, S. Robinson, C. Ruiz de Elvira, G. Taghipour, A. Carella, S. Mackinnon, M. Boogaerts, D. Caballero, M. Michallet, N. Russell, N 
. Schmitz on behalf of the EBMT Lymphoma Working Party
Overall results with conventional allogeneic stem cell transplantation (allo-SCT) in Hodgkin's disease (HD) patients are extremely poor due to a high transplant-related mortality (TRM). The use of a reduced-intensity conditioning regimen (RIC) could improve long-term survival by reducing TRM. We have compared the outcome in terms of overall survival (OS) and relapse rate (RR) between 99 patients allografted after a RIC and 163 patients undergoing a conventional allo-SCT from January/1997 to July/2001 and reported to the EBMT lymphoma database. Patients with 2 allo-SCT or 2 prior autologous stem cell transplantation (ASCT) had been previously excluded from the analysis. Age at diagnosis and at allo-SCT, disease characteristics at diagnosis, stem cell source, conditioning regimen and disease status before ASCT, time between diagnosis and allo-SCT, time interval between ASCT and allo-SCT and disease status at allo-SCT were similar in both groups. A previous ASCT was more frequent in the RIC group (55% vs 36%, p=0.002) as well as the use of peripheral blood (PB) as hematopoietic stem cell source for allo-SCT (89% vs 64% p<0.001) and a HLA identical sibling (80% vs 66%, p=0.049). TBI-containing regimens were more frequently used as conditioining protocols in the conventional group (11% vs 29%, p=0.007). The complete remission rate as well as the incidence of acute graft versus host disease were similar in both groups (40% vs 51%, p>0.1 and 55% vs 54%, p>0.1, respectively). The number of patients alive at 100 days and 1 year after allo-SCT was higher in the RIC group (80% vs 68%, p=0.036 and 48% vs 32%, p=0.036, respectively) probably due to a higher rate of toxic deaths in the conventional group (64% vs 44%, p=0.05). 
S6
Disease status at transplant is a major prognostic factor for outcome after allo-SCT and older age and the use of PB seem to be associated with a higher RR.
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Allogeneic hematopoietic stem cell transplantation in children with non-Hodgkin's lymphomas: an EBMT study on 136 patients A. Claviez, M. Tiemann, J. Harousseau, G. Dini, F. Mandelli, F. Fagioli, A. Schattenberg, C. Cordonnier, J. Cornish, J. Ortega, C. 
Peters, N. Schmitz on behalf of the EBMT Lymphoma and Pediatric Diseases Working Parties
The impact of allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with non-Hodgkin's lymphomas (NHL) has not been clarified. Therefore, a systematic study of all patients with NHL <18 years at diagnosis reported to EBMT excluding Burkitt's lymphomas has been initiated. Given the fact, that different NHL classifications have been widely used, a main focus of this analysis is a central pathological review according to WHO classification. So far, data from 136 pediatric NHL patients (87 male, 49 female) from 52 transplant centers in 16 countries have been received. Median age at diagnosis was 11.6 (0.3-17.9) years. Most common histologic subtypes were as follows: 70 lymphoblastic lymphomas (LBL; 58 T-LBL, 11 B-LBL, 1 not specified), 28 anaplastic large cell lymphomas (ALCL) (13 T-ALCL, 6 lymphohistiocytic, 5 Null-ALCL, 4 not specified), 11 diffuse large cell lymphomas (DLCL) and 5 peripheral T-NHL. At diagnosis, 86% of patients had advanced stages (III/IV) and 60% suffered from B symptoms. Patients had received 1-4 lines of chemotherapy and 25% were irradiated prior to transplantation. Nine percent of patients received an autograft, but subsequently relapsed. Status at allogeneic HSCT was as follows: CR1/CR-u n=19, PR n=7, sensitive relapse n=79, resistant relapse n=11, primary refractory n=15. Syngeneic donors were used in four, MRD in 95, MUD in 15 and mismatched related/unrelated donors in 22 patients, respectively. The majority of patients received bone marrow as stem cell source. A wide variety of conditioning regimens was used (myeloablative intensity given to 95%) and total body irradiation was used in 74%. Median age at HSCT was 12.9 (1.0-23.8) years. 95% of patients engrafted. Acute GvHD II-IV occurred in 32% and chronic GvHD developed in 25%. At a median follow-up of 1.2 (0-16) years 70 patients (51%) are alive. Overall survival (OS) was influenced by status at HSCT. 74% of patients transplanted in CR, 56% with sensitive relapse but only 27% with refractory disease survived (p=0.001). Among histologic subtypes, 64% of patients with ALCL, 57% with B-LBL and 45% with T-LBL are alive (p=n.s.). 36 of 136 patients (26%) relapsed following allogeneic HSCT. Relapses occurred in 21 of 70 LBL, but only in four of 28 ALCL. In conclusion, status at transplantation emerged as a prognostic factor. In addition, allogeneic HSCT may have a different impact on prognosis depending on the histologic subtype.
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Reduced early transplant-related mortality following allogeneic stem cell transplantation with fludarabine-based, reduced-intensity conditioning from matched related and unrelated donors in advanced Hodgkin's disease P. Anderlini, S. Acholonu, G. Okoroji, S. Giralt, N. Ueno, M. Donato, B. Andersson, I. Khouri, D. Couriel, C. Ippoliti, R. Valverde, R. Champlin (Houston, USA) Objective: To explore the feasibility of fludarabine (FDDP)-based, reduced-intensity conditioning in patients with advanced Hodgkin's Disease (HD) undergoing allogeneic Stem Cell Transplantation (SCT), as conventional myeloablative conditioning is known to be associated with unacceptably high transplant-related mortality. Methods: Allogeneic SCT following a FDDP-based conditioning regimen was carried out in 25 patients with very advanced HD who failed multiple conventional treatments (median chemotherapy regimens: 5; range 2-9), radiation therapy (17/25) and a prior autologous SCT (18/25). The median age was 30 years . Disease status at SCT was refractory relapse (n=8) and sensitive relapse (n=17). The median time to progression after autologous SCT was 9 months (2.5-52). The cell source was rhG-CSF-mobilized blood stem cells from an HLA-identical sibling (n=12) or matched unrelated donor marrow (MUD; n=13). The conditioning regimen was FDDP (25 mg/m sq IV x5)-cyclophosphamide (1 g/m sq IV x3)-± antithymocyte globulin 20 mg/kg IV x3 (FC±ATG) (n=13), and FDDP (25 mg/m sq IV x5)-melphalan 70 mg/m sq IV x2 (FM140) (n=12). 8/12 FM patients had a matched unrelated donor. Graft-vs-host disease (GVHD) prophylaxis was tacrolimus and methotrexate. Results: Myeloid recovery was prompt, with an absolute neutrophil count (ANC)>500/:L at day 11 (9-24). Median platelet recovery at 20K/:L was at day 17 (9-50), with 7 patients never dropping below 20K/:L after SCT. Chimerism and/or cytogenetic studies at day 30-100 indicate 100% donor-derived engraftment in 12/12 (100%) evaluable FM patients and in 7/12 (58%) evaluable FC±ATG patients. Day 100 transplant-related mortality (TRT) was only 2/25 (8%) overall. It was 0/12 (0%) in sibling SCT recipients, and was 2/13 (15%) in MUD SCT recipients. Both deceased patients were MUD transplant recipients and one had been conditioned with FM140. Acute GVHD occurred in 13/23 (56%) evaluable patients. Chronic GVHD was diagnosed in 11 patients (extensive in 9). Nine patients have expired (8/9 received FC±ATG), non-relapse mortality is 4/9 (44%) overall. Sixteen patients (64%) are alive (nine in remission) with a median follow-up of 10 months (1-51). Conclusion: Allogeneic SCT from related and unrelated donors with fludarabine-based, less intensive conditioning is feasible in very high-risk, heavily pretreated HD. It yielded very promising results on engraftment, acute GVHD and, in particular, early TRT rates. The FM140 regimen is seemingly better suited for these patients.
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Allogeneic hemopoietic stem cell transplantation for patients with lymphoma A.M. Raiola, T. Lamparelli, C. di Grazia, R. Oneto, B. Bruno, F. Gualandi, S. Bregante, A. Dominietto, V. Galbusera, E. Tedone, F. Frassoni, M.T. van Lint, A. Bacigalupo (Genoa, I) Background: Allogeneic hemopoietic stem cell transplantation (HSCT) is a therapeutic option increasingly used for patients with lymphomas. Long term follow up of these patients is however still scarce. Objective: To analyze the long term outcome of allogeneic transplants in lymphomas Methods: We report 70 patients allografted in our Unit between 1985 and 2002 with a median follow up of 1720 days for surviving patients (range 126-6444). The conditioning regimen was a conventional CY-TBI in 30 and a reduced intensity (thiotepa and cyclophosphamide) in 40. The median age of the patients was 36 years (17-65), the donor was an identical sibling (SIB) in 51, a mismatched family donor or an unrelated donor in 17, and an identical twin in 2. The diagnosis was Hodgkin's disease in 13, and non Hodgkin lymphoma in 57 (of these 35 were low intermediate grade, 17 were high grade and 5 were MCL). The majority of the patients (67%) had active disease at the time of transplant. Results: The overall survival at 15 years is 45% for the entire group, as well as for HD and NHL patients. The overall disease free survival at 15 years is 33% for the entire group (32% for HD and 34% for NHL patients). There was no major difference in survival between SIBs (49%) and alternative donor transplants (51%). Patients allografted with active disease had a 15 year survival of 41% compared to 52% for patients in remission. In patients with NHL the survival was superior for low/intermediate grade (51%) as compared to high grade NHL (41%) and MCL (40%). There was an overall (though modest) effect of chronic GvHD on relapse : 52% vs 24% relapse for patients with no/minimal vs limited/extensive cGvHD (p=0.04). This also translated in an advantage (though not significant) in survival (71% vs 59%) (p=0.3). There was no difference between marrow (n=44) (50%) and blood grafts (54% survival), or between conventional and reduced intensity grafts (43% vs 55%, p=0.3) . Conclusions: Long term survival can be achieved in lymphomas patients with an allogeneic HSCT, also when using an alternative donor, also in patients with active disease. Many of the survivors are free of the disease 10 years post-transplant. The effect of chronic GvHD is modest, but worth exploiting.
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High-risk aggressive non-Hodgkin's lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft: the long-term outcome is markedly influenced by presentation with aaIPI score 2 vs. 3 A. Cuttica, F. Zallio, M. Ladetto, M. Di Nicola, D. Caracciolo, M. Magni, C. Marinone, M. Dell'Aquila, M. Boccadoro, A. Pileri, M. Gianni, C. Tarella (Turin, Milan, I) The International Prognostic Index (IPI) is the most widely employed prognostic factor model to identify patients with aggressive non-Hodgkin'lymphoma who are unlikely to be cured with standard therapy. The age-adjusted (aa)-IPI is usually employed in patients aged less than 60 yrs. Aim of this study was to evaluate the impact of presentation with aaIPI score 2 or 3 in the outcome of high-risk aggressive lymphoma patients treated upfront with intensive chemotherapy and autograft. The analysis was performed on 69 consecutive patients (age: 18-63, median: 40 yrs.) treated with high-dose sequential (HDS) chemotherapy and peripheral blood progenitor cell (PBPC) autograft. All patients had either aaIPI score 2 (37 patients) or 3 (32 patients). Sixty patients had B-cell derived lymphoma (57 de novo diffuse large cell and 3 transformed lymphoma), the other nine had non-B cell aggressive lymphoma. Two regimens were employed: the original regimen (o-HDS), namely sequential delivery of cyclophosphamide, methotrexate and etoposide followed by PBPC autografting, was used between 1992 and 1996 (32 patients); an even more intensified protocol mainly characterized by the inclusion of one course of high-dose Ara-C (C-HDS) was employed between 1997-2000 (38 patients). There were 4 toxic deaths (5.8%), 2 among aaIPI 2 and 2 among aaIPI 3; 20 patients (3 aaIPI 2 and 17 aaIPI 3) had PR or disease progression, while 45 (65%) (32 aaIPI 2, 86% and 13 aaIPI 3, 41%) reached CR. At a median follow-up of 4.5 yrs., the 8-yr. overall survival (OS) and event-free survival (EFS) projections were 58% and 52% respectively. Patients with aaIPI 2 showed a significantly better outcome in terms of both OS (78% vs. 36% at 8 yrs.) and EFS (72% vs. 30% at 8 yrs.) compared to those with aaIPI 3. Similar results were observed when the analysis was restricted to the 60 patients with B-cell derived lymphoma. Thus, the results indicate that: i. the aaIPI score is applicable also in patients treated upfront with intensive chemotherapy and autograft; ii. the upfront use of HDS chemotherapy in aggressive lymphoma patients offers long-term survival projections superior to those historically achieved with conventional chemotherapy in aaIPI 2, while no real advantages are obtained in aaIPI 3; iii. the markedly different outcome of aaIPI 2 vs. 3 might explain the conflicting results reported with intensive treatments and autograft in high-risk aggressive lymphoma patients.
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Factors predicting response, toxicity and event-free survival following myeloablative radioimmunotherapy (RAIT) with I-131-rituximab for relapsed B-cell lymphoma
K. Schwarz, B. Schmidt, M. Sandherr, I. Wolf, K. Scheidhauer, M. Schwaiger, C. Peschel, C. von Schilling (Munich, D)
Objectives: Anti-CD20 RAIT with 131-I -rituximab is readily available, cheap and easy for centres with a radionuclide Tx facility. We sought to define parameters predicting outcome for pts undergoing RAIT. Methods: In an ongoing phase I/II trial, 27 pts with B NHL have now been treated at myeloablative doses. Pts were eligible if no curative treatment was available and/or if multiple salvage treatments had yielded less than PR. Of these, 25 have been followed until progression or remission of at least 1 year duration. Pt characteristics: 17 follicular / marginal zone, 4 mantle cell, 3 transformed, 3 primary aggressive lymphoma. Median no. of prior therapies 5 (2-11), median time from Dx to RAIT 44 (14-235) mo. 9 pts had more than 1 extranodal involvement, 8 bulky disease, 10 prior rituximab, and 10 prior aPBSCT. 5 had achieved only stable disease, 8 were frankly progressive at staging prior to RAIT. Results: All pts except early deaths and one further pt had ANC above 1.5 Gpt/L at d10 and were platelet transfusion-free at d20. 4 infection-associated deaths occurred, 8 febrile episodes (2 local abscess, 3 pneumonia, 3 FUO) and 2 mucositis in the neutropenic phase. All non-haem grade 4/5 tox occurred in pts with PD, with additional prior infection or prior aPBSCT. 3 cases of grade 2 to 3 pneumonitis occurred, all in pts post-TBI or post mantle field Rx. OR was 76%, with 48% CR. Achievement of CR depended significantly on histology (follicular vs. others), status prior to RAIT (PD vs. others), history of prior autotransplant and a trend for FLIP index (0 vs. above 0). Notably, there was only weak correlation with no. of previous non-myeloablative chemotherapy lines (p= 0.058). Prolonged EFS was associated with non-bulky disease, status prior to RAIT (see above), elevated LDH, and Hgb less than 12 g/dL. Conclusion: In these late-phase patients, factors selecting for response after conventional autotransplant also predict response and EFS following myeloablative RAIT. Nevertheless, results appear at least equivalent to conventional autotransplant at the cost of considerably less toxicity, opening up the perspective for pts not qualifying for TBI-based or BEAM regimens to undergo myeloablative treatment, should this option result in improved survival in current phase III trials.
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Multicenter prospective randomized GITMO trial comparing high dose sequential chemotherapy with autografting and CHOP both supplemented with rituximab in poor-risk follicular lymphoma: early evaluation on treatment feasibility and response rate M. Ladetto, I. Ricca, F. Benedetti, M. Liberati, U. Vitolo, M. Musso, A. Gallamini, V. Callea, V. Pavone, C. Almici, F. Di Raimondo, C. De Sousa, G. Fioritoni, I. Majolino, A. Olivieri, C. Patti, E. Pogliani, M. Astolfi, M. Boccadoro, A. M. Gianni, P. 
Corradini, C. Tarella on behalf of GITMO
A recently published multicenter GITMO trial has shown that an intensified version of the high-dose (hd) sequential chemotherapy regimen followed by autologous transplantation (i-HDS) is a feasible and simple purging-free regimen that appears particularly effective for patients with high-risk follicular lymphoma (FL) at diagnosis (Ladetto et al, Blood, 2002; 100:1559 -1565 . Recently, we have also demonstrated that i-HDS can be safely supplemented with Rituximab (R-HDS) with an impressive improvement of the in vivo purging effect on stem cell collections and very promising clinical results (Ladetto ed al, Leukemia, 2001; 15(12):1941-9) . Based on these experiences the GITMO has decided to launch a multicenter trial comparing R-HDS with a Rituximab supplemented CHOP (R-CHOP). Crossover was allowed for patients failing the R-CHOP arm. Patients were considered eligible if they had FL at diagnosis with an age-adjusted I.P.I. score >/=2 or >/=3 adverse parameters according to the Italian Lymphoma Intergroup (I.L.I.) score. Twenty-five Italian Centers and one Brasilian Center have so far actively participated to the study by enrolling at least one patient. So far, 78 patients have been enrolled: 70 were eligible due to the age-adjusted I.P.I. score and 8 were eligible due to the I.L.I. score, despite an I.P.I. score <2 . Centralized molecular analysis has been planned for all patients entering the study using either the Bcl-2 translocation or the immunoglobulin heavy chain rearrangement. The two arms appear so far well balanced in terms of age, sex, histological grade, and entry criteria (ageadjusted I.P.I. or I.L.I.) score. A molecular marker has been obtained in 38 of the 56 (67%) patients so far evaluated. Both treatments appeared to be feasible with two toxic death due to septic shock and sudden death, both occurring in the R-CHOP arm. Two patients enrolled in the R-HDS arm were withdrawn before autografting while already in CR due to poor cardiac performance detected by echocardiography. 49 patients are so far evaluable for response (23 in the R-HDS arm and 26 in the R-CHOP arm). Overall CR rate was 73%, (61% the R-CHOP arm and 87% in the R-HDS arm). Among patients achieving CR, two relapses were noted in the R-HDS and four in the R-CHOP arm.
In conclusion, these preliminary results, seem to indicate a trend toward a better outcome (in term of CR achievement an eventfree survival) for patients enrolled in the R-HDS arm.
Oral Session: Multiple myeloma O135
High-dose therapy autotransplantation/intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial chemotherapy. Results of a prospective randomized trial from the Spanish Cooperative Group Pethema J. Blade, A. Sureda, J.M. Ribera, J. Diaz Mediavilla, J. Garcia Larana, L. Palomera, J. Fernandez Calvo, J.M. Marti, P. Giraldo, F. Carbonell, M. Callis, J. Trujillo, S. Gardella, M.J. Moro, A. Barez, A. Soler, L. Font, M. Fontanilles, J. San Miguel on behalf of the Hospital Clinic, Barcelona, PETHEMA Background: High-dose therapy/stem cell rescue (HDT/SCT) is offered to most younger patients with multiple myeloma (MM) patients as part of the initial therapy. However, the role of HDT/SCT in the management of patients with MM is controversial. Aim: The aim of this study was to compare HDT/SCT and continued conventional chemotherapy in MM patients responding to the initial treatment. Patients and Methods: From May 1994 to October 1999, 216 patients (122M/94F, median age 56 yrs, stage II or III, ECOG < 3) were registered. The initial chemotherapy consisted of 4 courses of alternating BVMCP/VBAD. Responding patients received either 8 additional courses of BVMCP/VBAD (arm A) or intensification with HDT/SCT -melphalan 140 mg/m2/TBI 12 Gys or melphalan 200 mg/m2 (arm B). Maintenance treatment consisted of alpha-interferon and dexamethasone in both arms. Results: One-hundred and eighty five patients responded to initial chemotherapy (CR: 15%, PR: 68%, and MR: 17%). Twenty-one of these responding patients were not randomized due to different reasons. Among the 164 randomized patients 83 were allocated to continued chemotherapy and 81 to HDT/SCT. The degree of initial response as well as prognostic features did not differ in both groups. The results were updated as of November 15, 2002 after a median follow-up of 49 months from the initiation of treatment and analyzed on an intention-to-treat basis. CR (negative electrophoresis) was significantly higher in the HDT/SCT arm (30 vs. 11%, p=0.002). However, PFS was not significantly different between HDT/SCT and conventional chemotherapy (median, 43 vs. 34 mos; p=NS) and the OS was similar in both groups (median, 62 vs. 56 mos.; p=NS) . Conclusions: This study shows that HDT/SCT intensification significantly increases complete remission rate but has no significant impact on PFS and OS in myeloma patients responding to initial chemotherapy.
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CD34 + selection of autologous transplants in patients with newly diagnosed myeloma: final report of an EBMT phase III randomized study J.H. Bourhis, Y. Bouko, S. Koscielny, H. Greinix, G. Derigs, G. Salles, W. Feremans, M. Bakkus, J. Apperley, D. Samson, G. Gahrton, J. Pico, H. Goldschmidt on behalf of the EBMT Multiple Myeloma Subcommittee CD34+ selection of PBSC has been used in MM as a mean to reduce relapse linked with tumor cells contamination and thus improving outcome. However, a clinical benefit has not been demonstrated at the onset of this study. From May 1995 to November 1999, 127 pts from 17 EBMT centers with newly diagnosed advanced MM were included into this phase III trial and 112 pts are analysed. Responders to 3 cycles of VAD were randomized to receive a CD34+ selected graft (arm A, n=55) or an unselected graft (arm B, n=57). PBPC were harvested following mobilization with cyclophosphamide 4g/m² and G-CSF (Filgrastim). Conditioning regimen in both arms was TBI and melphalan 140 mg/m². CD34+ selection was performed in arm A using the CellPro Ceprate-SC device and resulted in a median purity of 88.5% and yield of 63%. Molecular analysis showed a median tumor cell depletion of 1.93 log (0.87-5.2). The médian number of CD34+ cells reinfused was 7.2x106 CD34 cells/kg (1.4 -50.4) in arm A and 14.4x106 CD34 cells/kg (1.8-99.2) in arm B. The median time to neutrophil engraftment (ANC>O.5x109/l) was 10 days in arm A (8-14) and 10 days in arm B (8-21). The median time to platelets engraftment (plts>20x109/l) was 11 days in both arms but one patient in arm A never reached 20x109/l platelets without supportive transfusions. 13 episodes of serious infections between the time of neutrophil engraftment and day 100 were reported in arm A compared to only 1 in arm B. All the infections were viral except 1 bacterial and 1 protozoal. For 3 patients in arm A, these infections were fatal (parainfluenza, CMV and myocarditis of infective etiology). The overall transplant mortality was 2.7% (3 patients in arm A). There was no significant difference in CR rate at 1 year as defined by EBMT/IBMTR/ABMTR criteria (16% in arm A and 15% in arm B). There is so far no significant difference in EFS and OS. Median follow-up is 47 months in both arms. Probability of OS at 3 years is 71% in arm A and 81.5% in arm B. The 3 year relapse risk is 54.05% in arm A vs. 30.5% in arm B. In summary, CD34+ selection resulted in a 1.9 tumor cell depletion without delay in hematological recovery. However, long term follow up analysis of these patients shows no significant clinical benefit for progression free survival. Moreover, the increased incidence of bacterial and viral life threatening infections in the CD34+ selected arm, similar to those for allogeneic BMT recipients, legitimate systematic prophylaxis regimens and raise clinical concerns . Altogether, these results suggest new approaches in CD34+ selection to circumvent immune recovery delay.
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10-year survival in myeloma: a new endpoint for testing potentially curative strategies? R. Powles, B. Sirohi, S. Singhal, S. Kulkarni, R. Saso, C. Horton, S. Sankpal, J. Treleaven, J. Mehta (Sutton, UK) We have previously shown that patients with myeloma who survive longer than 10 years in complete remission (CR) appear
